Rethinking CRSwNP: A Visual Framework for Targeting Epithelial-Driven Inflammation
Released On
June 30, 2025
Expires On
June 30, 2026
Media Type
Internet
Completion Time
30 minutes
Specialty
Allergy & Immunology, Otolaryngology, Rhinology
Topic(s)
Chronic Rhinosinusitis with Nasal Polyps, Asthma, Allergies
This activity is provided by National Jewish Health and supported by an independent educational grant from AstraZeneca Pharmaceuticals.
Credit Available
- Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of allergists/immunologists, otolaryngologists, rhinologists, and advanced practice providers.
Program Overview
Epithelial-driven inflammatory airway disease in chronic rhinosinusitis with nasal polyps (CRSwNP) represents a critical challenge for healthcare providers due to its chronic nature, heterogeneity, and significant impact on patients’ quality of life. Complex interactions between the airway epithelium, structural cells, and the immune system, with epithelial cytokines such as thymic stromal lymphopoietin (TSLP), interleukin-33 (IL-33), and interleukin-25 (IL-25) play pivotal roles in disease pathogenesis and progression.
In this mobile-friendly, interactive infographic activity, learners will review the definition and clinical features of CRSwNP; explore inflammatory pathways in a self-paced animation of pathophysiology in CRSwNP; and review comprehensive management strategies, including current and emerging treatment options for CRSwNP.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify the features in the pathophysiology of upper and lower airways associated with epithelial-driven inflammatory airway diseases
- Assess the role of epithelial cytokines in the inflammatory pathways in CRSwNP
- Evaluate emerging biologic therapies, targeting epithelial cytokines, for the management of CRSwNP
Faculty
Eileen Wang, MD, MPH
Associate Professor
Division of Allergy & Immunology Clinical Services
Department of Medicine
National Jewish Health
Denver, Colorado
Ashoke (Ash) Khanwalkar, MD
Assistant Professor
Otolaryngology - Head and Neck Surgery
University of Colorado Medicine
Aurora, Colorado
Accreditation Statement
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Physician Credit Designation Statement
National Jewish Health designates this enduring material for a maximum of 0.5 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.
All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.
Faculty Disclosures
- Eileen Wang, MD, MPH reports the following relevant financial relationships:
- Advisory Board: AstraZeneca, GlaxoSmithKline
- Consultant: AstraZeneca, GlaxoSmithKline
- Investigator: AstraZeneca, Genentech, GlaxoSmithKline, Sanofi
- Speaker: AstraZeneca, Genentech
- Ashoke (Ash) Khanwalkar, MD reports the following relevant financial relationships:
- Advisory Board: GlaxoSmithKline, SoundHealth
- Speaker: GlaxoSmithKline, Aerin Medical
Planner and Reviewer Disclosures
Meghan Brenner, MA has no relevant financial relationships to disclose.
Bryce Chitanavong, MBA has no relevant financial relationships to disclose.
Andrea Harshman, MHA, CHCP has no relevant financial relationships to disclose.
Ashoke (Ash) Khanwalkar, MD reports the following relevant financial relationships:
- Advisory Board: GlaxoSmithKline, SoundHealth
- Speaker: GlaxoSmithKline, Aerin Medical
Harold Nelson, MD has no relevant financial relationships to disclose.
Eileen Wang, MD, MPH reports the following relevant financial relationships:
- Advisory Board: AstraZeneca, GlaxoSmithKline
- Consultant: AstraZeneca, GlaxoSmithKline
- Investigator: AstraZeneca, Genentech, GlaxoSmithKline, Sanofi
- Speaker: AstraZeneca, Genentech
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Complete the post-test with a passing score of 2 out of 3 correct and submit the evaluation form.
A certificate will be emailed to the participant.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses. Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications, and warnings.
Disclaimer
National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.
By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.
Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.
Contact Information
For CME questions please contact: [email protected].